Drug Trial Radar · NCT07815301
Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, open-label, parallel-group, non-inferiority trial will evaluate whether sequential tapering and discontinuation of beta-blockers is non-inferior to maintenance of the baseline stable beta-blocker dose in adult patients with obstructive hypertrophic cardiomyopathy (oHCM) who have achieved predefined clinical and hemodynamic stability during mavacamten treatment. Eligible participants will be randomly assigned in a 1:1 ratio to a sequential tapering and discontinuation group or a baseline stable-dose maintenance group. In the tapering group, the beta-blocker dose will be reduced stepwise approximately every 4 weeks, with complete discontinuation planned at Week 12 if predefined safety and stability criteria are met. Participants will be followed through Week 24. The primary objective is to compare the proportion of participants who maintain clinical and hemodynamic stability without protocol-defined treatment failure through Week 24. The feasibility and safety of complete beta-blocker discontinuation will also be evaluated.
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Beta-Blocker Sequential Tapering and DiscontinuationDrug
Participants will undergo sequential tapering of their baseline beta-blocker therapy. The daily beta-blocker dose will be reduced approximately every 4 weeks following a planned dose pathway of approximately 100%, 75%, 50%, 25%, and 0% of the randomization baseline daily dose. Complete discontinuation is planned at Week 12 if predefined clinical, hemodynamic, and safety criteria are met. Dose reduction may be paused or delayed, and dose rollback or rescue treatment may be implemented according to protocol-defined criteria.
Beta-Blocker Baseline Stable-Dose MaintenanceDrug
Participants will continue the beta-blocker type, dosing frequency, and daily dose that were stable at randomization throughout the 24-week randomized follow-up period, unless dose modification is clinically required because of efficacy or safety concerns according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Week 24 Clinical and Hemodynamic Strategy Success RateTime frame: From randomization through Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.